The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Boyko A.N.

Pirogov Russian National Research Medical University;
Federal Center of Brain Research and Neurotechnologies of the Federal Medical Biological Agency

Alifirova V.M.

Siberian State Medical University

Lukashevich I.G.

Orden of the Red Banner of Labor City Clinical Hospital No. 1

Goncharova Z.A.

Rostov State Medical University

Greshnova I.V.

Regional Clinical Hospital

Zaslavsky L.G.

Pavlov First Saint Petersburg State Medical University

Kotov S.V.

Vladimirsky Moscow Regional Research Clinical Institute

Malkova N.A.

State Novosibirsk Regional Clinical Hospital;
Novosibirsk State Medical University

Mishin G.N.

Pyatigorsk City Clinical Hospital No. 2

Parshina E.V.

Semashko Nizhny Novgorod Regional Clinical Hospital

Poverennova I.Ye.

Seredavin Samara Regional Clinical Hospital

Prakhova L.N.

N. Bechtereva Institute of the Human Brain

Sivertseva S.A.

Medical and Sanitary unit «Neftyanik»

Smagina I.V.

Altai State Medical University;
Regional Clinical Hospital

Totolyan N.A.

Academician I.P. Pavlov First Saint Petersburg State Medical University

Trinitatsky Yu.V.

Rostov Regional Clinical Hospital

Trushnikova T.N.

Wagner Perm State Medical University

Khabirov F.A.

City Clinical Hospital No. 7;
Kazan State Medical Academy — Branch of the Russian Medical Academy of Continuing Professional Education

Chefranova J.Yu.

Belgorod Regional Clinical Hospital of St. Joasaph

Shchur S.G.

Municipal Filatov Clinical Hospital No. 15

Dudin V.A.

Center for Cardiology and Neurology»

Pokhabov D.V.

Federal Siberian Scientific and Clinical Center

Bolsun D.D.

AO BIOCAD

Eremeeva A.V.

JSC BIOCAD

Linkova Yu.N.

AO BIOCAD

Zinkina-Orikhan A.V.

AO BIOCAD

Efficacy and safety of antiCD20 monoclonal antibody divozilimab during 48-week treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4/MIRANTIBUS

Authors:

Boyko A.N., Alifirova V.M., Lukashevich I.G., Goncharova Z.A., Greshnova I.V., Zaslavsky L.G., Kotov S.V., Malkova N.A., Mishin G.N., Parshina E.V., Poverennova I.Ye., Prakhova L.N., Sivertseva S.A., Smagina I.V., Totolyan N.A., Trinitatsky Yu.V., Trushnikova T.N., Khabirov F.A., Chefranova J.Yu., Shchur S.G., Dudin V.A., Pokhabov D.V., Bolsun D.D., Eremeeva A.V., Linkova Yu.N., Zinkina-Orikhan A.V.

More about the authors

Views: 2623

Downloaded: 88


To cite this article:

Boyko AN, Alifirova VM, Lukashevich IG, et al. . Efficacy and safety of antiCD20 monoclonal antibody divozilimab during 48-week treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4/MIRANTIBUS. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(7‑2):43‑52. (In Russ.)
https://doi.org/10.17116/jnevro202312307243

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.